Back to Trials
NCT05218850PHASE2Recruiting

The Use of Butyrate Therapy in Pediatric Ulcerative Colitis

Children's Hospital Los Angeles

Start Date

6/29/2022

Completion Date

6/30/2027

Summary

Butyrate is an important metabolite produced by the gut microbiome and has been shown as a helpful therapy in ulcerative colitis. This is a feasibility study to determine the efficacy of butryate enemas in pediatric ulcerative colitis.

Detailed Description

butyrate enemas will be administered for 12 weeks to children ages 7 to 21 with mild to moderate ulcerative colitis to determine if butyrate therapy can help improve the clinical disease in those children. standard management of the disease will be performed during these 12 weeks including routine laboratory studies and endoscopy.

Eligibility Criteria

Age Range: 7 years to 21 years

Inclusion Criteria: * 7-21 years, mild to moderate ulcerative colitis Exclusion Criteria: * UC therapy within 4 weeks of study medication initiation * infectious colitis, -pregnancy

Interventions

DRUG

Butyrate

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

Ulcerative Colitis

Locations

Children's Hospital Los Angeles

Los Angeles, California 90027

United States